Singapore, Oct. 8 -- If the opening day of BioJapan 2026 diagnosed the gap between Japanese science and global deals, the second day at PACIFICO Yokohama got down to the practical business of closing it. The tone on 8 October was less about what Japan lacks and more about the specific routes, rules and tools now available to fix it.

The phrase that best captured the mood came from Saisei Ventures' afternoon investment forum: "Japan's Third Way." The idea is simple but ambitious. In a biopharma world increasingly shaped by the United States and China, Japan does not need to imitate either superpower. It can build a distinct identity on its original science, its platforms and, as several sessions made clear, a regulatory system that is sta...